MNPR
Monopar TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade A from latest DB weights. Momentum 88.7 / Value 41.1
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +20.2.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
89
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $112.00
Why
Momentum89 · Δ7d +20.2
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
52% active weight
Current posture
7d trendImproving
Δ7d
+20.2
Δ21d
+57.2
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 88.7 / Value 41.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$410.39M
Beta
1.54
Shares Out
6.68M
P/E (TTM) · Derived
-14.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-36.88
Rev YoY
-
EPS YoY
-30.2%
Gross Margin
-
Op Margin
-
Net Debt
-$60.21M
Current Ratio
56.10
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology